Why have TAF therapy done in China specifically?

China offers this therapy at a significantly lower cost—approximately $400 per year—compared to $1,500–$3,000 in Western countries, due to domestic generic manufacturing and government price controls. Chinese hepatology centers perform high-volume monitoring, with experienced specialists managing thousands of hepatitis B cases annually. Access to branded TAF (e.g., Vemlidy) and generics is reliable, and clinics in cities like Beijing or Shanghai provide English-speaking coordinators for international patients.